Targeting inflammation and oxidative stress in atrial fibrillation: Role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins

Antioxidants and Redox Signaling

Volumn 20, Issue 8, 2014, Pages 1268-1285

  Pinho Gomes, Ana Catarina ^a   Reilly, Svetlana ^a   Brandes, Ralf P ^b   Casadei, Barbara ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTI-INFLAMMATORY AGENTS; ATRIAL FIBRILLATION; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NADH, NADPH OXIDOREDUCTASES; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84894450156     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5542     Document Type: Review

References (179)

1. Ad N, Henry L, and Hunt S. The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation. Eur J Cardiothorac Surg 40: 70-76, 2011.
2. Adabag AS, Nelson DB, and Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 154: 1140-1145, 2007.
3. Adam O, Frost G, Custodis F, Sussman MA, Schafers HJ, Bohm M, and Laufs U. Role of Rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 50: 359-367, 2007.
4. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M, Aubier M, Mercadier JJ, Reed JC, and Hatem SN. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 34: 1577-1586, 1999.
5. Akar FG, Aon MA, Tomaselli GF, and O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest 115: 3527-3535, 2005.
6. Anselmi A, Possati G, and Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg 88: 326-333, 2009.
7. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, and Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 54: 669-677, 2009.
8. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, Antonopoulos AS, Demosthenous M, Miliou A, Psarros C, Marinou K, Sfyras N, Economopoulos G, Casadei B, Channon KM, and Stefanadis C. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPHoxidase activity. Circulation 122: S66-S73, 2010.
9. Antoniades C, Demosthenous M, Reilly S, Margaritis M, Zhang MH, Antonopoulos A, Marinou K, Nahar K, Jayaram R, Tousoulis D, Bakogiannis C, Sayeed R, Triantafyllou C, Koumallos N, Psarros C, Miliou A, Stefanadis C, Channon KM, and Casadei B. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment. J Am Coll Cardiol 59: 60-70, 2012.
10. Antoniades C, Van-Assche T, Shirodaria C, Diesch J, Antonopoulos AS, Lee J, Cunnington C, Tousoulis D, Stefanadis C, Casadei B, Taggart D, Channon KM, and Leeson P. Preoperative sCD40L levels predict risk of atrial fibrillation after off-pump coronary artery bypass graft surgery. Circulation 120: S170-S176, 2009.
11. Aon MA, Cortassa S, Marban E, and O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem 278: 44735-44744, 2003.
12. Atkins GB and Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res 100: 1686-1695, 2007.
13. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, and Chung MK. Inflammation as a risk factor for atrial fibrillation. Circulation 108: 3006-3010, 2003.
14. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, and Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670-1681, 2010.
15. Beauchamp P, Yamada KA, Baertschi AJ, Green K, Kanter EM, Saffitz JE, and Kleber AG. Relative contributions of connexins 40 and 43 to atrial impulse propagation in synthetic strands of neonatal and fetal murine cardiomyocytes. Circ Res 99: 1216-1224, 2006.
16. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
17. Belevych AE, Terentyev D, Terentyeva R, Nishijima Y, Sridhar A, Hamlin RL, Carnes CA, and Gyorke S. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. Cardiovasc Res 90: 493-502, 2011.
18. Bikou O, Thomas D, Trappe K, Lugenbiel P, Kelemen K, Koch M, Soucek R, Voss F, Becker R, Katus HA, and Bauer A. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res 92: 218-225, 2011.
19. Bjorkhem-Bergman L, Lindh JD, and Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br J Clin Pharmacol 72: 164-165, 2011.
20. Brandes RP and Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res 65: 16-27, 2005.
21. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, and Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96: 3542-3548, 1997.
22. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, and Nattel S. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res 105: 1213-1222, 2009.
23. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC, Jr., Harrison DG, and Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106: 2854-2858, 2002.
24. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, and Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 14: 1385-1413, 2012.
25. Cangemi R, Celestini A, Calvieri C, Carnevale R, Pastori D, Nocella C, Vicario T, Pignatelli P, and Violi F. Different behaviour of NOX2 activation in patients with paroxysmal/persistent or permanent atrial fibrillation. Heart 98: 1063-1066, 2012.
26. Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, McCarthy PM, Bauer JA, and Van Wagoner DR. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89: E32-E38, 2001.
27. Carnicer R, Crabtree MJ, Sivakumaran V, Casadei B, and Kass DA. Nitric oxide synthases in heart failure. Antioxid Redox Signal 18: 1078-1099, 2013.
28. Chan AW, Bhatt DL, Chew DP, Reginelli J, Schneider JP, Topol EJ, and Ellis SG. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 107: 1750-1756, 2003.
29. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, and Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468: 1115-1118, 2010.
30. Chen YB, Shu J, Yang WT, Shi L, Guo XF, Wang FG, and Qian YY. Meta-analysis of randomized trials comparing the effectiveness of on-pump and off-pump coronary artery bypass. Chin Med J (Engl) 125: 338-344, 2012.
31. Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, Eagle KA, and Saint S. Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analysis. Arch Surg 147: 181-189, 2012.
32. Chung MK, Martin DO, Sprecher D,Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, and Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104: 2886-2891, 2001.
33. Cicha I, Schneiderhan-Marra N, Yilmaz A, Garlichs CD, and Goppelt-Struebe M. Monitoring the cellular effects of HMG-CoA reductase inhibitors in vitro and ex vivo. Arterioscler Thromb Vasc Biol 24: 2046-2050, 2004.
34. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, Cook NR, Buring JE, and Albert CM. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 31: 1730-1736, 2010.
35. Conway DS, Buggins P, Hughes E, and Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol 43: 2075-2082, 2004.
36. Danchin N, Fauchier L, Marijon E, Barnay C, Furber A, Mabo P, Bernard P, Blanc JJ, Jouven X, Le Heuzey JY, Charbonnier B, Ferrieres J, and Simon T. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FASTMI register. Heart 96: 1809-1814, 2010.
37. Davis LM, Kanter HL, Beyer EC, and Saffitz JE. Distinct gap junction protein phenotypes in cardiac tissues with disparate conduction properties. J Am Coll Cardiol 24: 1124-1132, 1994.
38. Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, and Guasti L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost 106: 363-370, 2011.
39. Dernellis J and Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25: 1100-1107, 2004.
40. Dudley SC, Jr., Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, and Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation 112: 1266-1273, 2005.
41. Duffy HS and Wit AL. Is there a role for remodeled connexins in AF? No simple answers. J Mol Cell Cardiol 44: 4-13, 2008.
42. Dupont E, Ko Y, Rothery S, Coppen SR, Baghai M, Haw M, and Severs NJ. The gap-junctional protein connexin40 is elevated in patients susceptible to postoperative atrial fibrillation. Circulation 103: 842-849, 2001.
43. Eager KR and Dulhunty AF. Activation of the cardiac ryanodine receptor by sulfhydryl oxidation is modified by Mg2 + and ATP. J Membr Biol 163: 9-18, 1998.
44. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Muller-Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dorr M, Ozaki K, Roberts JD, Smith JG, Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, Borkovich M, Harris TB, Lin H, Volker U, Volzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann HE, Witteman JC, Kao WH, Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, McKnight B, Sjogren M, Newman AB, Liu Y, Gollob MH, Melander O, Tanaka T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, and Kaab S. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 44: 670-675, 2012.
45. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, Spitz DR, Shea MA, Colbran RJ, Mohler PJ, and Anderson ME. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133: 462-474, 2008.
46. Fauchier L, Clementy N, and Babuty D. Statin therapy and atrial fibrillation: systematic review and updated metaanalysis of published randomized controlled trials. Curr Opin Cardiol 28: 7-18, 2013.
47. Fleissner F and Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal 15: 933-948, 2011.
48. Forstermann U and Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 33: 829-837, 837a-837d, 2012.
49. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96: 1180-1184, 1997.
50. Fukahara K, Kotoh K, Doi T, Misaki T, and Sumi S. Impact of preoperative atrial fibrillation on the late outcome of offpump coronary artery bypass surgery. Eur J Cardiothorac Surg 38: 366-372, 2010.
51. Ghaffari N, Ball C, Kennedy JA, Stafford I, and Beltrame JF. Acute modulation of vasoconstrictor responses by pravastatin in small vessels. Circ J 75: 1506-1514, 2011.
52. Glantzounis GK, Tsimoyiannis EC, Kappas AM, and Galaris DA. Uric acid and oxidative stress. Curr Pharm Des 11: 4145-4151, 2005.
53. Goette A, Hammwohner M, Bukowska A, Scalera F, Martens-Lobenhoffer J, Dobrev D, Ravens U, Weinert S, Medunjanin S, Lendeckel U, and Bode-Boger SM. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol 154: 141-146, 2012.
54. Gollob MH, Jones DL, Krahn AD, Danis L, Gong XQ, Shao Q, Liu X, Veinot JP, Tang AS, Stewart AF, Tesson F, Klein GJ, Yee R, Skanes AC, Guiraudon GM, Ebihara L, and Bai D. Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med 354: 2677-2688, 2006.
55. Greiser M, Lederer WJ, and Schotten U. Alterations of atrial Ca(2 + ) handling as cause and consequence of atrial fibrillation. Cardiovasc Res 89: 722-733, 2011.
56. Guerra JM, Everett TH 4th, Lee KW, Wilson E, and Olgin JE. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 114: 110-118, 2006.
57. Hagendorff A, Schumacher B, Kirchhoff S, Luderitz B, and Willecke K. Conduction disturbances and increased atrial vulnerability in Connexin40-deficient mice analyzed by transesophageal stimulation. Circulation 99: 1508-1515, 1999.
58. Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, Hippelainen M, Juvonen T, Hartikainen J, and Hakala T. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA 297: 1562-1567, 2007.
59. Han W, Fu S, Wei N, Xie B, Li W, Yang S, Li Y, Liang Z, and Huo H. Nitric oxide overproduction derived from inducible nitric oxide synthase increases cardiomyocyte apoptosis in human atrial fibrillation. Int J Cardiol 130: 165-173, 2008.
60. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY, and Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27: 949-953, 2006.
61. Hellsten-Westing Y. Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle. Histochemistry 100: 215-222, 1993.
62. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, von Birgelen C, Haude M, Heusch G, and Erbel R. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106: 2180-2183, 2002.
63. Holowatz LA, Santhanam L, Webb A, Berkowitz DE, and Kenney WL. Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans. J Physiol 589: 2093-2103, 2011.
64. Hsieh MH, Lin YJ, Wang HH, Lo LW, Chang SL, Yan YL, Chou TY, Chen SA, and Yeh HI. Functional characterization of atrial electrograms in a pacing-induced heart failure model of atrial fibrillation: importance of regional atrial connexin40 remodeling. J Cardiovasc Electrophysiol 24: 573-582, 2013.
65. Hung CY, Lin CH, Loh el-W, Ting CT, and Wu TJ. CHADS(2) score, statin therapy, and risks of atrial fibrillation. Am J Med 126: 133-140, 2013.
66. Igarashi T, Finet JE, Takeuchi A, Fujino Y, Strom M, Greener ID, Rosenbaum DS, and Donahue JK. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation 125: 216-225, 2012.
67. Ishii Y, Schuessler RB, Gaynor SL, Yamada K, Fu AS, Boineau JP, and Damiano RJ, Jr. Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation. Circulation 111: 2881-2888, 2005.
68. Jones SP, Teshima Y, Akao M, and Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93: 697-699, 2003.
69. Jougasaki M, Ichiki T, Takenoshita Y, and Setoguchi M. Statins suppress interleukin-6-induced monocyte chemoattractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159: 1294-1303, 2010.
70. Kaireviciute D, Aidietis A, and Lip GY. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies. Eur Heart J 30: 410-425, 2009.
71. Kallergis EM, Manios EG, Kanoupakis EM, Mavrakis HE, Kolyvaki SG, Lyrarakis GM, Chlouverakis GI, and Vardas PE. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 94: 200-204, 2008.
72. Kanagaratnam P, Cherian A, Stanbridge RD, Glenville B, Severs NJ, and Peters NS. Relationship between connexins and atrial activation during human atrial fibrillation. J Cardiovasc Electrophysiol 15: 206-216, 2004.
73. Kato T, Iwasaki YK, and Nattel S. Connexins and atrial fibrillation: filling in the gaps. Circulation 125: 203-206, 2012.
74. Kim MH. Do the benefits of anti-arrhythmic drugs outweigh the associated risks? A tale of treatment goals in atrial fibrillation. Expert Rev Clin Pharmacol 5: 163-171, 2012.
75. Kim SJ, Choisy SC, Barman P, Zhang H, Hancox JC, Jones SA, and James AF. Atrial remodeling and the substrate for atrial fibrillation in rat hearts with elevated afterload. Circ Arrhythm Electrophysiol 4: 761-769, 2011.
76. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, Pillai R, Channon KM, and Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 97: 629-636, 2005.
77. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, and Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 51: 68-74, 2008.
78. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, and Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol 28: 142-147, 2008.
79. Korantzopoulos P, Letsas KP, and Liu T. Xanthine oxidase and uric acid in atrial fibrillation. Front Physiol 3: 150, 2012.
80. Koyama T, Tada H, Sekiguchi Y, Arimoto T, Yamasaki H, Kuroki K, Machino T, Tajiri K, Zhu XD, Kanemoto-Igarashi M, Sugiyasu A, Kuga K, Nakata Y, and Aonuma K. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J Am Coll Cardiol 56: 1463-1472, 2010.
81. Kulik A, Singh JP, Levin R, Avorn J, and Choudhry NK. Association between statin use and the incidence of atrial fibrillation following hospitalization for coronary artery disease. Am J Cardiol 105: 1655-1660, 2010.
82. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 1004-1010, 2000.
83. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4: 181-189, 2004.
84. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, and Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27: 943-948, 2007.
85. Laufs U and Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
86. Lee HY, Youn SW, Cho HJ, Kwon YW, Lee SW, Kim SJ, Park YB, Oh BH, and Kim HS. FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2. Cardiovasc Res 97: 143-152, 2012.
87. Letsas KP, Korantzopoulos P, Filippatos GS, Mihas CC, Markou V, Gavrielatos G, Efremidis M, Sideris A, and Kardaras F. Uric acid elevation in atrial fibrillation. Hellenic J Cardiol 51: 209-213, 2010.
88. Letsas KP, Siklody CH, Korantzopoulos P, Weber R, Burkle G, Mihas CC, Kalusche D, and Arentz T. The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation. Int J Cardiol 164: 94-98, 2013.
89. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, and Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database Syst Rev 4: CD008493, 2012.
90. Liew R, Khairunnisa K, Gu Y, Tee N, Yin NO, Naylynn TM, and Moe KT. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrosis and development of an arrhythmogenic substrate. Circ J 77: 1171-1179, 2013.
91. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, Leong DP, Brooks AG, Young GD, Kistler PM, Kalman JM, Worthley MI, and Sanders P. Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 61: 852-860, 2013.
92. Lip GY and Tse HF. Management of atrial fibrillation. Lancet 370: 604-618, 2007.
93. LiuG,Abramson JJ, ZableAC, and Pessah IN.Direct evidence for the existence and functional role of hyperreactive sulfhydryls on the ryanodine receptor-triadin complex selectively labeled by the coumarin maleimide 7-diethylamino-3-(4¢-maleimidylphenyl)-4-methylcoumarin. Mol Pharmacol 45: 189-200, 1994.
94. Liu T, Li G, Li L, and Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 49: 1642-1648, 2007.
95. Liu T, Li L, Korantzopoulos P, Goudevenos JA, and Li G. Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. Am J Cardiol 101: 1749-1752, 2008.
96. Liuba I, Ahlmroth H, Jonasson L, Englund A, Jonsson A, Safstrom K, and Walfridsson H. Source of inflammatory markers in patients with atrial fibrillation. Europace 10: 848-853, 2008.
97. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, Walsh K, Isner JM, and Asahara T. HMGCoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108: 399-405, 2001.
98. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, and Benjamin EJ. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110: 1042-1046, 2004.
99. Loffredo L, Angelico F, Perri L, and Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and metaanalysis. BMC Cardiovasc Disord 12: 107, 2012.
100. Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, and Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 99: 1421-1424, 2007.
101. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, and Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 94: 157-161, 2004.
102. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, and Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 106: 331-336, 2002.
103. Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, and Tavazzi L. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J 30: 2327-2336, 2009.
104. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, and Cohn JN. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149: 548-557, 2005.
105. Mangialardi G, Monopoli A, Ongini E, Spinetti G, Fortunato O, Emanueli C, and Madeddu P. Nitric oxidedonating statin improves multiple functions of circulating angiogenic cells. Br J Pharmacol 164: 570-583, 2011.
106. Marengo JJ, Hidalgo C, and Bull R. Sulfhydryl oxidation modifies the calcium dependence of ryanodine-sensitive calcium channels of excitable cells. Biophys J 74: 1263-1277, 1998.
107. Marin F, Pascual DA, Roldan V, Arribas JM, Ahumada M, Tornel PL, Oliver C, Gomez-Plana J, Lip GY, and Valdes M. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97: 55-60, 2006.
108. McLean DL, Kim J, Kang Y, Shi H, Atkins GB, Jain MK, and Chun HJ. Apelin/APJ signaling is a critical regulator of statin effects in vascular endothelial cells-brief report. Arterioscler Thromb Vasc Biol 32: 2640-2643, 2012.
109. McManus DD, Saczynski JS, Lessard D, Kinno M, Pidikiti R, Esa N, Harrington J, and Goldberg RJ. Recent trends in the incidence, treatment, and prognosis of patients with heart failure and atrial fibrillation (the Worcester Heart Failure Study). Am J Cardiol 111: 1460-1465, 2013.
110. Miceli A, Fino C, Fiorani B, Yeatman M, Narayan P, Angelini GD, and Caputo M. Effects of preoperative statin treatment on the incidence of postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 87: 1853-1858, 2009.
111. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, and Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380: 581-590, 2012.
112. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, and Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104: 174-180, 2001.
113. Morgera T, Di Lenarda A, Dreas L, Pinamonti B, Humar F, Bussani R, Silvestri F, Chersevani D, and Camerini F. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J 124: 455-467, 1992.
114. Nao T, Ohkusa T, Hisamatsu Y, Inoue N, Matsumoto T, Yamada J, Shimizu A, Yoshiga Y, Yamagata T, Kobayashi S, Yano M, Hamano K, and Matsuzaki M. Comparison of expression of connexin in right atrial myocardium in patients with chronic atrial fibrillation versus those in sinus rhythm. Am J Cardiol 91: 678-683, 2003.
115. Neef S, Dybkova N, Sossalla S, Ort KR, Fluschnik N, Neumann K, Seipelt R, Schondube FA, Hasenfuss G, and Maier LS. CaMKII-dependent diastolic SR Ca2 + leak and elevated diastolic Ca2 + levels in right atrial myocardium of patients with atrial fibrillation. Circ Res 106: 1134-1144, 2010.
116. Nishijima Y, Sridhar A, Bonilla I, Velayutham M, Khan M, Terentyeva R, Li C, Kuppusamy P, Elton TS, Terentyev D, Gyorke S, Zweier JL, Cardounel AJ, and Carnes CA. Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology. Cardiovasc Res 91: 71-79, 2011.
117. Nishino T, Okamoto K, Eger BT, and Pai EF. Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 275: 3278-3289, 2008.
118. Ohnesorge N, Viemann D, Schmidt N, Czymai T, Spiering D, Schmolke M, Ludwig S, Roth J, Goebeler M, and Schmidt M. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). J Biol Chem 285: 26199-26210, 2010.
119. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, Platia E, Feld GK, Akiyama T, Brodsky MA, and Greene HL. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol 43: 1201-1208, 2004.
120. Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S, Iijima K, Akishita M, and Ouchi Y. Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol 30: 2205-2211, 2010.
121. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, and Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 110: II45-II49, 2004.
122. Pasterkamp G and van Lammeren GW. Pleiotropic effects of statins in atherosclerotic disease. Expert Rev Cardiovasc Ther 8: 1235-1237, 2010.
123. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, and Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114: 1455-1461, 2006.
124. Pelat M, Dessy C, Massion P, Desager JP, Feron O, and Balligand JL. Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/-mice in vivo. Circulation 107: 2480-2486, 2003.
125. Pellegrini CN, Vittinghoff E, Lin F, Hulley SB, and Marcus GM. Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart 95: 704-708, 2009.
126. Podzuweit T, Braun W, Muller A, and Schaper W. Arrhythmias and infarction in the ischemic pig heart are not mediated by xanthine oxidase-derived free oxygen radicals. Basic Res Cardiol 82: 493-505, 1987.
127. Psychari SN, Apostolou TS, Sinos L, Hamodraka E, Liakos G, and Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 95: 764-767, 2005.
128. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 25: 399-405, 2010.
129. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, and Macfarlane PW. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 342: d1250, 2011.
130. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, Munz BM, Muller P, Steendijk P, Reil GH, Allessie MA, Bohm M, and Neuberger HR. Aldosterone promotes atrial fibrillation. Eur Heart J 33: 2098-2108, 2012.
131. Reilly SN, Jayaram R, Nahar K, Antoniades C, Verheule S, Channon KM, Alp NJ, Schotten U, and Casadei B. Atrial sources of reactive oxygen species vary with the duration and substrate of atrial fibrillation: implications for the antiarrhythmic effect of statins. Circulation 124: 1107-1117, 2011.
132. Ridker PM, Thuren T, Zalewski A, and Libby P. Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162: 597-605, 2011.
133. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, Schwoerer AP, Lau D, Fu X, Klingel K, Sydow K, Didie M, Seniuk A, von Leitner EC, Szoecs K, Schrickel JW, Treede H, Wenzel U, Lewalter T, Nickenig G, Zimmermann WH, Meinertz T, Boger RH, Reichenspurner H, Freeman BA, Eschenhagen T, Ehmke H, Hazen SL, Willems S, and Baldus S. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 16: 470-474, 2010.
134. Saffitz JE. Douglas P. Zipes Lecture. Biology and pathobiology of cardiac connexins: from cell to bedside. Heart Rhythm 3: 102-107, 2006.
135. Sakabe M, Fujiki A, Sakamoto T, Nakatani Y, Mizumaki K, and Inoue H. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Electrophysiol 23: 1130-1135, 2012.
136. Sato K, Nuki T, Gomita K, Weyand CM, and Hagiwara N. Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndrome. Atherosclerosis 213: 33-39, 2010.
137. Savelieva I, Kakouros N, Kourliouros A, and Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 13: 610-625, 2011.
138. Sawaya SE, Rajawat YS, Rami TG, Szalai G, Price RL, Sivasubramanian N, Mann DL, and Khoury DS. Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. Am J Physiol Heart Circ Physiol 292: H1561-H1567, 2007.
139. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, Keaney JF, Jr., Wang TJ, Vasan RS, and Benjamin EJ. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 104: 92-96, 2009.
140. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Tofler GH, Selhub J, Jacques PF, Wolf PA, Magnani JW, Ellinor PT, Wang TJ, Levy D, Vasan RS, and Benjamin EJ. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 121: 200-207, 2010.
141. Shan J, Betzenhauser MJ, Kushnir A, Reiken S, Meli AC, Wronska A, Dura M, Chen BX, and Marks AR. Role of chronic ryanodine receptor phosphorylation in heart failure and beta-adrenergic receptor blockade in mice. J Clin Invest 120: 4375-4387, 2010.
142. Shan J, Xie W, Betzenhauser M, Reiken S, Chen BX, Wronska A, and Marks AR. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. Circ Res 111: 708-717, 2012.
143. Shen B, Smith RS, Jr., Hsu YT, Chao L, and Chao J. Kruppellike factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitricoxide synthase expression. J Biol Chem 284: 35471-35478, 2009.
144. Shiroshita-Takeshita A, Brundel BJ, Lavoie J, and Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res 69: 865-875, 2006.
145. Shiroshita-Takeshita A, Sakabe M, Haugan K, Hennan JK, and Nattel S. Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation 115: 310-318, 2007.
146. Shiroshita-Takeshita A, Schram G, Lavoie J, and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110: 2313-2319, 2004.
147. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, and Cantrell DA. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 9: 513-521, 2008.
148. Spach MS and Starmer CF. Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. Cardiovasc Res 30: 337-344, 1995.
149. Spodick DH. Arrhythmias during acute pericarditis. A prospective study of 100 consecutive cases. JAMA 235: 39-41, 1976.
150. Suleiman M, Koestler C, Lerman A, Lopez-Jimenez F, Herges R, Hodge D, Bradley D, Cha YM, Brady PA, Munger TM, Asirvatham SJ, Packer DL, and Friedman PA. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebocontrolled, randomized trial. Heart Rhythm 9: 172-178, 2012.
151. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, and Shyy JY. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114: 2655-2662, 2006.
152. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, Oikawa Y, Koike A, Nagashima K, Kirigaya H, Yajima J, Sawada H, Aizawa T, and Yamashita T. Genderspecific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 76: 607-611, 2012.
153. Tamariz L, Agarwal S, Soliman EZ, Chamberlain AM, Prineas R, Folsom AR, Ambrose M, and Alonso A. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 108: 1272-1276, 2011.
154. Tchou GD, Wirka RC, Van Wagoner DR, Barnard J, Chung MK, and Smith JD. Low prevalence of connexin-40 gene variants in atrial tissues and blood from atrial fibrillation subjects. BMC Med Genet 13: 102, 2012.
155. Tselentakis EV, Woodford E, Chandy J, Gaudette GR, and Saltman AE. Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. J Surg Res 135: 68-75, 2006.
156. van der Velden HM, Ausma J, Rook MB, Hellemons AJ, van Veen TA, Allessie MA, and Jongsma HJ. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc Res 46: 476-486, 2000.
157. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, and Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107: 2926-2931, 2003.
158. Villarreal G, Jr., Zhang Y, Larman HB, Gracia-Sancho J, Koo A, and Garcia-Cardena G. Defining the regulation of KLF4 expression and its downstream transcriptional targets in vascular endothelial cells. Biochem Biophys Res Commun 391: 984-989, 2010.
159. Virani SS, Nambi V, Razavi M, Lee VV, Elayda M, Wilson JM, and Ballantyne CM. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 155: 541-546, 2008.
160. Wagner AH, Kohler T, Ruckschloss U, Just I, and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000.
161. Wagner RJ, Martin KA, Powell RJ, and Rzucidlo EM. Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR. Am J Physiol Cell Physiol 299: C119-C127, 2010.
162. Wagner S, Rokita AG, Anderson ME, and Maier LS. Redox regulation of sodium and calcium handling. Antioxid Redox Signal 18: 1063-1077, 2013.
163. Wakili R, Voigt N, Kaab S, Dobrev D, and Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 121: 2955-2968, 2011.
164. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, and Isner JM. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105: 3017-3024, 2002.
165. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22: 300-305, 2002.
166. Watanabe E. Uric acid and atrial fibrillation-cause or other association? Circ J 76: 584-585, 2012.
167. Wetzel U, Boldt A, Lauschke J, Weigl J, Schirdewahn P, Dorszewski A, Doll N, Hindricks G, Dhein S, and Kottkamp H. Expression of connexins 40 and 43 in human left atrium in atrial fibrillation of different aetiologies. Heart 91: 166-170, 2005.
168. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, and Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 93: 8745-8749, 1996.
169. Wirka RC, Gore S, Van Wagoner DR, Arking DE, Lubitz SA, Lunetta KL, Benjamin EJ, Alonso A, Ellinor PT, Barnard J, Chung MK, and Smith JD. A common connexin-40 gene promoter variant affects connexin-40 expression in human atria and is associated with atrial fibrillation. Circ Arrhythm Electrophysiol 4: 87-93, 2011.
170. Yaktubay Dondas N, Sucu N, Coskun Yilmaz B, Kaplan HM, Ozeren M, Karaca MK, Vezir O, and Singirik E. Molecular mechanism of vasorelaxant and antiatherogenic effects of the statins in the human saphenous vein graft. Eur J Pharmacol 666: 150-157, 2011.
171. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, Suma H, Sawada H, and Aizawa T. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 74: 262-270, 2010.
172. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa Y, Kawada T, Brownlee M, Nishikawa T, and Araki E. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinasedependent cyclooxygenase-2 expression in macrophages. Circ Res 100: 1442-1451, 2007.
173. Yoshino S, Yoshikawa A, Hamasaki S, Ishida S, Oketani N, Saihara K, Okui H, Kuwahata S, Fujita S, Ichiki H, Ueya N, Iriki Y, Maenosono R, Miyata M, and Tei C. Atrial fibrillation-induced endothelial dysfunction improves after restoration of sinus rhythm. Int J Cardiol 168: 1280-1285, 2013.
174. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, and Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92: 1379-1383, 2003.
175. Zeiser R, Maas K, Youssef S, Durr C, Steinman L, and Negrin RS. Regulation of different inflammatory diseases by impacting the mevalonate pathway. Immunology 127: 18-25, 2009.
176. Zhang M, Perino A, Ghigo A, Hirsch E, and Shah AM. NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal 18: 1024-1041, 2013.
177. Zhou Q and Liao JK. Pleiotropic effects of statins.-Basic research and clinical perspectives. Circ J 74: 818-826, 2010.
178. Zhou X, Du JL, Yuan J, and Chen YQ. Statins therapy can reduce the risk of atrial fibrillation in patients with acute coronary syndrome: a meta-analysis. Int J Med Sci 10: 198-205, 2013.
179. Zissimopoulos S, Docrat N, and Lai FA. Redox sensitivity of the ryanodine receptor interaction with FK506-binding protein. J Biol Chem 282: 6976-6983, 2007.